{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T04:02:46Z","timestamp":1749528166563,"version":"3.41.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"am","delay-in-days":343,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.clml.2025.02.008","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T16:38:44Z","timestamp":1740501524000},"page":"e466-e473.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Factors Predicting Spontaneous Regression in Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Diseases"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9610-7797","authenticated-orcid":false,"given":"Kosuke","family":"Takayama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruka","family":"Yamanokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Shinmura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3210-9491","authenticated-orcid":false,"given":"Yuto","family":"Hibino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayoko","family":"Shirafuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2738-1267","authenticated-orcid":false,"given":"Jun","family":"Nukui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marika","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3887-9001","authenticated-orcid":false,"given":"Haruka","family":"Teshigawara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshimi","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maki","family":"Hagihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.clml.2025.02.008_bib0001","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/ijc.24141","article-title":"Autoimmunity and lymphomagenesis","volume":"124","author":"Goldin","year":"2009","journal-title":"Int J Cancer"},{"issue":"5","key":"10.1016\/j.clml.2025.02.008_bib0002","doi-asserted-by":"crossref","first-page":"642","DOI":"10.3109\/14397595.2016.1141740","article-title":"Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population: a nationwide cohort study in Japan","volume":"26","author":"Harigai","year":"2016","journal-title":"Mod Rheumatol"},{"issue":"1","key":"10.1016\/j.clml.2025.02.008_bib0003","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.prp.2008.08.006","article-title":"EBV-associated diffuse large B-cell lymphoma in a psoriatic treated with methotrexate","volume":"205","author":"Hsiao","year":"2009","journal-title":"Pathol Res Pract"},{"issue":"1","key":"10.1016\/j.clml.2025.02.008_bib0004","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1080\/14397595.2021.1879362","article-title":"Characteristics of rheumatoid arthritis with immunodeficiency-associated lymphoproliferative disorders to regress spontaneously by the withdrawal of methotrexate and their clinical course: a retrospective, multicenter, case-control study","volume":"32","author":"Kuramoto","year":"2022","journal-title":"Mod Rheumatol"},{"issue":"20","key":"10.1016\/j.clml.2025.02.008_bib0005","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2025.02.008_bib0006","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/ijc.11582","article-title":"Lymphoproliferative disorders in autoimmune diseases in Japan: analysis of clinicopathological features and Epstein-Barr virus infection","volume":"108","author":"Hoshida","year":"2004","journal-title":"Int J Cancer"},{"issue":"12","key":"10.1016\/j.clml.2025.02.008_bib0007","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/ajh.21003","article-title":"Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: relationship with type of latent Epstein-Barr virus infection","volume":"82","author":"Miyazaki","year":"2007","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.clml.2025.02.008_bib0008","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1038\/modpathol.2009.131","article-title":"Immunomodulator agent-related lymphoproliferative disorders","volume":"22","author":"Hasserjian","year":"2009","journal-title":"Mod Pathol"},{"issue":"5","key":"10.1016\/j.clml.2025.02.008_bib0009","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1111\/j.1349-7006.2010.01517.x","article-title":"Clinicopathologic correlations of diffuse large B-cell lymphoma in rheumatoid arthritis patients treated with methotrexate","volume":"101","author":"Niitsu","year":"2010","journal-title":"Cancer Sci"},{"issue":"1","key":"10.1016\/j.clml.2025.02.008_bib0010","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/ejh.12116","article-title":"Methotrexate\/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression","volume":"91","author":"Ichikawa","year":"2013","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.clml.2025.02.008_bib0011","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3899\/jrheum.130270","article-title":"A clinical, pathological, and genetic characterization of methotrexate-associated lymphoproliferative disorders","volume":"41","author":"Yamakawa","year":"2014","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.clml.2025.02.008_bib0012","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1080\/10428194.2017.1369073","article-title":"Clinicopathologic investigation of methotrexate-induced lymphoproliferative disorders, with a focus on regression","volume":"59","author":"Tokuhira","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2025.02.008_bib0013","doi-asserted-by":"crossref","unstructured":"Cheson B.D., Fisher R.I., Barrington S.F., et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-hodgkin lymphoma: the Lugano classification. J Clin Oncol. Alliance: Australasian Leukaemia and Lymphoma Group, Eastern Cooperative Oncology Group. 2014;32(27):3059-3068. doi: 10.1200\/JCO.2013.54.8800.","DOI":"10.1200\/JCO.2013.54.8800"},{"issue":"3","key":"10.1016\/j.clml.2025.02.008_bib0014","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.clml.2025.02.008_bib0015","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3899\/jrheum.140533","article-title":"Incidence of malignancy and the risk of lymphoma in Japanese patients with rheumatoid arthritis compared to the general population","volume":"42","author":"Hashimoto","year":"2015","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.clml.2025.02.008_bib0016","first-page":"322","article-title":"Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication","volume":"34","author":"Hoshida","year":"2007","journal-title":"J Rheumatol"},{"issue":"7","key":"10.1016\/j.clml.2025.02.008_bib0017","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1097\/PAS.0000000000001271","article-title":"Methotrexate-associated lymphoproliferative disorders in patients with rheumatoid arthritis: clinicopathologic features and prognostic factors","volume":"43","author":"Kurita","year":"2019","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"10.1016\/j.clml.2025.02.008_bib0018","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s10067-017-3634-5","article-title":"Characteristics and risk factors of lymphoproliferative disorders among patients with rheumatoid arthritis concurrently treated with methotrexate: a nested case-control study of the IORRA cohort","volume":"36","author":"Shimizu","year":"2017","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.clml.2025.02.008_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13547500701674063","article-title":"Serum soluble interleukin 2 receptor \u03b1 in human cancer of adults and children: a review","volume":"13","author":"Bien","year":"2008","journal-title":"Biomarkers"},{"issue":"6","key":"10.1016\/j.clml.2025.02.008_bib0020","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/art.42809","article-title":"Effect of recent antirheumatic drug on features of rheumatoid arthritis-associated lymphoproliferative disorders","volume":"76","author":"Hoshida","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.clml.2025.02.008_bib0021","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/hon.2790","article-title":"Association of Epstein-Barr virus with regression after withdrawal of immunosuppressive drugs and subsequent progression of iatrogenic immunodeficiency-associated lymphoproliferative disorders in patients with autoimmune diseases","volume":"38","author":"Fujimoto","year":"2020","journal-title":"Hematol Oncol"},{"issue":"10","key":"10.1016\/j.clml.2025.02.008_bib0022","doi-asserted-by":"crossref","first-page":"e10576","DOI":"10.15252\/emmm.201910576","article-title":"The IL-6 signaling complex is a critical driver, negative prognostic factor, and therapeutic target in diffuse large B-cell lymphoma","volume":"11","author":"Hashwah","year":"2019","journal-title":"EMBO Mol Med"},{"issue":"1","key":"10.1016\/j.clml.2025.02.008_bib0023","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/14397595.2020.1847775","article-title":"Treatment of rheumatoid arthritis after regression of lymphoproliferative disorders in patients treated with methotrexate: a retrospective, multi-center descriptive study","volume":"32","author":"Nakano","year":"2022","journal-title":"Mod Rheumatol"},{"issue":"9","key":"10.1016\/j.clml.2025.02.008_bib0024","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1002\/acr.22306","article-title":"Association of higher methotrexate dose with lymphoproliferative disease onset in rheumatoid arthritis patients","volume":"66","author":"Kameda","year":"2014","journal-title":"Arthritis Care Res"},{"issue":"3","key":"10.1016\/j.clml.2025.02.008_bib0025","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/art.21675","article-title":"Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis","volume":"54","author":"Baecklund","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.clml.2025.02.008_bib0026","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1093\/rheumatology\/kex002","article-title":"Distinct patterns of lymphocyte count transition in lymphoproliferative disorder in patients with rheumatoid arthritis treated with methotrexate","volume":"56","author":"Saito","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.clml.2025.02.008_bib0027","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1007\/s00296-017-3764-8","article-title":"Clinical characteristics of methotrexate-associated lymphoproliferative disorders: relationship between absolute lymphocyte count recovery and spontaneous regression","volume":"37","author":"Takanashi","year":"2017","journal-title":"Rheumatol Int"},{"issue":"2","key":"10.1016\/j.clml.2025.02.008_bib0028","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3960\/jslrt.19039","article-title":"The clinical impact of absolute lymphocyte count in peripheral blood among patients with methotrexate \u2013 Associated lymphoproliferative disorders","volume":"60","author":"Tokuhira","year":"2020","journal-title":"J Clin Exp Hematop"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025000709?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025000709?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T13:51:57Z","timestamp":1749477117000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025000709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2152265025000709"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.02.008","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factors Predicting Spontaneous Regression in Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Diseases","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}